Found 18 clinical trials
Study of Lademirsen (SAR339375) in Patients With Alport Syndrome (HERA)
Primary Objectives: To assess the efficacy of lademirsen (SAR339375) in reducing the decline in renal function To assess the safety and tolerability of lademirsen (SAR339375) in subjects with Alport syndrome Secondary Objectives: To assess plasma pharmacokinetic (PK) parameters of the parent compound and its metabolites To assess the potential formation …
- 0 views
- 23 Nov, 2021
- 23 locations
virtualtesting
(*) Coronary heart disease (CHD), cerebrovascular manifestation, peripheral arterial occlusive disease (PAOD) (**) For cardiovascular events (e.g. diabetes mellitus, renal function glomerular filtration rate (GFR) < 60 ml/min) Exclusion Criteria: - Planned or existing pregnancy, cancer, drug or alcohol abuse, dementia, or general inability to understand the content of the …
- 0 views
- 30 Aug, 2022
- 1 location
A Medical Research Study Designed to Determine if Venglustat Can be a Future Treatment for ADPKD Patients
Secondary Objectives: To determine the effect of venglustat on the rate of renal function decline (Stage 1) and on the rate of TKV growth (Stage 2). To evaluate the pharmacokinetics (PK) of venglustat in Autosomal Dominant Polycystic Kidney Disease patients (Stages 1 and 2).
- 0 views
- 04 Dec, 2020
- 81 locations
Relation Between Mean Arterial Pressure and Renal Resistive Index in the Early Phase of Septic Shock
This study evaluates if improvement of renal resistive index when mean arterial pressure increase (at 65 mmHg to 85 mmHg) in early phase of septic shock is predictive of better renal survival.
- 0 views
- 16 Feb, 2024
- 1 location
The Renal Deterioration Between Adjusted Dose TDF and Switching to TAF in CHB With Renal Impairment
Hepatitis B patients taking TDF have adjusted their dosage due to impair renal function, for example, from 1 time per day to every 48 hours or every 72 hours. This group of patients does not have a clear evidence-based recommendation for choosing a reduced dose of TDF or change to …
- 0 views
- 16 Feb, 2024
- 1 location
Study of Lademirsen (SAR339375) in Patients With Alport Syndrome (HERA)
Primary Objectives: To assess the efficacy of lademirsen (SAR339375) in reducing the decline in renal function To assess the safety and tolerability of lademirsen (SAR339375) in subjects with Alport syndrome Secondary Objectives: To assess plasma pharmacokinetic (PK) parameters of the parent compound and its metabolites To assess the potential formation …
- 0 views
- 23 Nov, 2021
Everolimus Plus Mycophenolic Acid for Kidney Preservation in Liver Transplant Recipients With Impaired Kidney Function
Primary Aim Assess the effect of Everolimus with or without Mycophenolate Mofetil versus Tacrolimus plus Mycophenolate Mofetil therapy on renal function measured by Glomerular Filtration Rate (GFR). Secondary Aims Compare the efficacy of Everolimus plus Mycophenolate Mofetil versus Tacrolimus plus Mycophenolate Mofetil therapy as measured by the following: Biopsy-confirmed acute …
- 0 views
- 16 Feb, 2024
- 1 location
Renal Impairment Study of PF-06700841
The purpose of this study is to characterize the effect of kidney impairment on the blood concentrations of PF-06700841 and its major metabolite. Findings from this study will be used to develop dosing recommendations so that the dose and/or dosing interval may be adjusted appropriately in the presence of kidney …
- 0 views
- 16 Feb, 2024
- 3 locations
Liberation From Acute Dialysis
The goal of the LIBERATE-D clinical trial is to improve outcomes for patients recovering from dialysis-requiring acute kidney injury (AKI-D). The impact of a conservative dialysis strategy compared to standard clinical practice of thrice-weekly dialysis will be examined to help generate knowledge for how to guide delivery of dialysis to …
- 0 views
- 16 Feb, 2024
- 2 locations
A Comparison of Rocuronium 0.6 mg/kg and Remifentanil 2 g/kg in Elderly Patients Over 80 Years
The number of elderly patients above 80 years is increasing and a large proportion of these patients will require surgery and anesthesia. During anesthesia neuromuscular blocking agents (NMBA) are administered to facilitate intubating conditions and reduce the trauma to the larynx and vocal cords. There is a risk of residual …
- 0 views
- 16 Feb, 2024
- 2 locations
- 1
- 2